ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
George V. Letsou
Igor D. Gregoric
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Letsou, G. V.
Right arrow Articles by Frazier, O. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Letsou, G. V.
Right arrow Articles by Frazier, O. H.
Related Collections
Right arrow Mechanical Circulatory Assistance

Ann Thorac Surg 2003;76:1167-1170
© 2003 The Society of Thoracic Surgeons

Original article: cardiovascular

Continuous axial-flow left ventricular assist device (Jarvik 2000) maintains kidney and liver perfusion for up to 6 months

George V. Letsou, MDb*, Timothy J. Myers, BSa, Igor D. Gregoric, MDa, Reynolds Delgado, MDa, Nyma Shah, BSa, Kimberly Robertson, BSa, Branislav Radovancevic, MDa, O. H. Frazier, MDa

a Texas Heart Institute, St. Luke's Episcopal Hospital, Houston, Texas, USA
b The University of Texas Medical School, Houston, Texas, USA

Accepted for publication April 18, 2003.

* Address reprint requests to Dr Letsou, Department of Cardiothoracic and Vascular Surgery, The University of Texas-Houston Medical School, 6431 Fannin St, MSB 1.210, Houston, TX 77030, USA.
e-mail: george.v.letsou{at}uth.tmc.edu

BACKGROUND: The Jarvik 2000 axial flow left ventricular assist device (LVAD), under development for the past decade, has the potential to support patients temporarily until cardiac transplantation or as a permanent circulatory support, without the size limitations of other implantable systems.

METHODS: To assess its ability to perfuse the kidneys and liver, we monitored renal and hepatic function in 10 patients who received the Jarvik 2000 LVAD as a bridge to transplantation. Left ventricular assistance was maintained for up to 214 days (> 6 months), and renal and hepatic function were monitored at least weekly.

RESULTS: Renal function before LVAD implantation in these patients was normal in 7 (creatinine, < 1.5) and moderately impaired in 3 (creatinine, 1.2 to 2.0). Hepatic function was normal in 7 patients before LVAD implantation (total bilirubin< 1.2; serum glutamic-oxaloacetic transaminase (SGOT), < 40; serum glutamic-pyruvic transaminase (SGPT), < 50) and normal at the time of transplantation in all 10 patients. Of the 3 patients with abnormal hepatic function before LVAD implantation, 1 patient had also had moderate renal dysfunction.

CONCLUSIONS: Despite reduced pulsatility, the Jarvik 2000 LVAD improves or maintains excellent renal and hepatic function during periods of circulatory assistance in patients awaiting transplantation.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
H. Habazettl, M. Kukucka, Y. G. Weng, W. M. Kuebler, R. Hetzer, H. Kuppe, and A. R. Pries
Arteriolar Blood Flow Pulsatility in a Patient Before and After Implantation of an Axial Flow Pump.
Ann. Thorac. Surg., March 1, 2006; 81(3): 1109 - 1111.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2003 by The Society of Thoracic Surgeons.